Off-the-Shelf immune cells take on Hard-to-Treat cancers
NCT ID NCT06773091
First seen Apr 06, 2026 · Last updated Jun 20, 2026 · Updated 10 times
Summary
This early-stage trial tests NK042, a ready-made natural killer cell therapy made from healthy donors, in 76 people with advanced solid tumors that no longer respond to standard treatments. Participants first receive two chemotherapy drugs to prepare their immune system, then get an infusion of NK042. The main goals are to check safety and find the right dose, while also looking for signs that the tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NK042 (natural killer cells from healthy donors) plus chemotherapy drugs (fludarabine and cyclophosphamide) given beforehand to prepare the body
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early (Phase 1) and small trial focused on safety, so it may not show strong tumor shrinkage. The chemotherapy pre-treatment can cause side effects, and the cell therapy itself may cause immune reactions or other serious adverse events.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.